Pegaptanib in the treatment of wet, age-related macular degeneration.

摘要: Age-related macular degeneration (AMD) is a major cause of severe visual loss worldwide. Neovascular (wet) AMD accounts for 90% the associated with disorder and vascular endothelial growth factor (VEGF) has been shown to play role in neovascularization permeability, causes AMD, making it an ideal target therapeutic intervention. To utilize this strategy, pegaptanib, aptamer that specifically binds blocks VEGF165, VEGF isoform primarily responsible abnormal permeability was developed. Following encouraging preclinical trials, clinical trials showed pegaptanib stabilized vision reduced risk majority patients some showing improvement. Pegaptanib maintained good safety profile only occasional adverse effects. Even greater success achieved when used combination another such as photodynamic therapy or bevacizumab, pan inhibitor. Further investigation wet particularly other modes therapy, should be encouraged.